Although SGLT2 inhibitors have become standard in the management of heart failure with preserved and reduced ejection fraction, their use in patients with ATTR amyloidosis with cardiac disease remains largely unstudied. Most major trials have excluded this population, and current guidelines do not address it.
A retrospective cohort analysis, presented at the American College of Physicians (ACP) Internal Medicine (IM) Meeting 2025, held April 3-5, in New Orleans, Louisiana, by Justin Riley Lam, MD, medical resident at Albert Einstein Medical Center in Philadelphia, Pennsylvania, evaluated the impact of SGLT2 inhibitors in patients with ATTR amyloidosis compared to those who were not using SGLT2 inhibitors.
HCPLive spoke with Lam to learn more about the analysis and its findings. Among these findings, investigators found that those on SGLT2 inhibitors had a lower mortality rate compared to those not on it. These participants also had a lower rate of using intravenous diuretics, which Lam and colleagues used as a surrogate marker for hospitalizations, because they could not use hospitalizations as an outcome in their database.
“Most people who have ATTR amyloidosis already have heart failure, so they are already usually on it, which is a good thing. And you know, with the recent studies pushing for either preserved ejection fraction or reduced ejection fraction, this gives us a better shot at treating this condition,” Lam told HCPLive during the meeting.
Lam has no relevant disclosures to report.